All In Biotech

Drug Trial Radar · NCT05586802

Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome

Dissecting the Importance of Sex Steroids Balance for Metabolic and Reproductive Health in Men With Klinefelter Syndrome: a Randomized Controlled Study

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Mar 21, 2023

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Georgios PapadakisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 16 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study seeks primarily to determine whether modulation of systemic and testicular sex steroids balance by aromatase inhibitors will positively affect the metabolic health and spermatogenesis of men with Klinefelter syndrome (KFS) as compared to the current state of the art for each issue. Secondary objectives of this study are (i) to unravel the heterogeneity of the reproductive and metabolic phenotype of men with KFS by performing a multi-omic analysis in a large cohort at baseline; (ii) to evaluate the efficacy of semaglutide-induced weight loss to achieve metabolic and reproductive benefit in men with Klinefelter syndrome as compared to standard testosterone replacement; (ii) to assess whether addition of hCG to aromatase inhibitors further increases intratesticular testosterone and promotes spermatogenesis in men with KFS.

Conditions

  • Klinefelter Syndrome

Interventions

  • AnastrozoleDrug

    This will be an experimental treatment for 26 weeks in Group 1 Arm A and Arm B as well for Group 2 Arm D

  • SemaglutideDrug

    This will be an experimental treatment for 26 weeks in Group 2 Arm E

  • human chorionic gonadotropinDrug

    This will be an experimental treatment for 26 weeks in addition to anastrozole in Group 1 - Arm B

  • Testosterone gelDrug

    This will be an active comparator for 26 weeks in Group 2 - Arm C

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Design 1 : sperm retrieval rate at mTESE biopsyTime frame: mTESE biopsy 26 weeks after hormonal intervention
  2. Design 2 : change in insulin resistance index (HOMA-IR)Time frame: From baseline to week 26 of intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Service of Endocrinology, Diabetes & Metabolism

    Lausanne, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.